MinorGabapentinoids (antiepileptics)×Tripeptide antioxidant (γ-glutamyl-cysteinyl-glycine); cofactor of glutathione S-transferase
Updated · Methodology
Mechanism
Gabapentin is not metabolised, does not bind to plasma proteins and is excreted unchanged by the kidneys (Neurontin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Aluminium- and magnesium-containing antacids reduce its absorption, and opioids and other CNS depressants increase CNS depression (Neurontin SmPC, AEMPS, section 4.5). Glutathione is a tripeptide. It is not authorised as an oral medicine in Spain and is sold as a food supplement. Intestinal and hepatic gamma-glutamyltransferase breaks it down: in 7 healthy volunteers, 3 g of oral glutathione did not raise plasma glutathione (Witschi et al., 1992). With 250–1000 mg a day for 6 months, glutathione stores in blood rose by 17–35% (randomised trial, Richie et al., 2015). The combination with gabapentin has not been studied, and no mechanism by which glutathione would change the absorption, elimination or effect of gabapentin is known.
Symptoms
No symptoms caused by this combination have been described. Together with opioids and other CNS depressants, gabapentin can cause drowsiness, sedation and respiratory depression (Neurontin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5).
Management
The combination can be used and no dose change is needed. There are no data on an interaction, and no mechanism that would cause one is known (Neurontin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Oral glutathione is largely broken down in the gut and liver, while gabapentin is not metabolised, so they share no metabolic pathway (Neurontin SmPC, AEMPS, section 5.2; Witschi et al., 1992).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Neurontin 300 mg cápsulas duras (gabapentina) (2026)– AEMPS, CIMA, nº registro 60621, revisión 01/2026, secciones 4.4 y 4.5
- European journal of clinical pharmacology: The systemic availability of oral glutathione (1992)– Witschi A, et al. Eur J Clin Pharmacol. 1992;43(6):667-9. PMID 1362956
- European journal of nutrition: Randomized controlled trial of oral glutathione supplementation on body stores of glutathione (2015)– Richie JP Jr, et al. Eur J Nutr. 2015;54(2):251-63. PMID 24791752